Adaptive dosing of immunotherapy shows promise for Tough-to-Treat liver cancer

NCT ID NCT07689175

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This trial investigates whether a combination of two immunotherapy drugs, nivolumab and ipilimumab, can control advanced liver cancer in patients with moderate cirrhosis (Child-Pugh B). The dosing is adjusted based on how each patient responds. The study aims to see how many patients achieve disease control, such as tumor shrinkage or stability.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
nivolumab and ipilimumab
What this could lead to
If successful, this could offer a new treatment option for people with advanced liver cancer and moderate cirrhosis who currently have few choices.
What could go wrong
This is a small, early-phase trial, so results may not apply broadly. Immunotherapy can cause serious side effects, including inflammation of organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75390, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.